Correction: Uncovering potential molecular biomarkers for cancer-associated secondary lymphedema through integrated analyses of RNA-sequencing, machine learning, and clinical data - Report - MDSpire
Advertisement
Correction: Uncovering potential molecular biomarkers for cancer-associated secondary lymphedema through integrated analyses of RNA-sequencing, machine learning, and clinical data
Clinical Report: Correction on Identifying Potential Molecular Biomarkers for Cancer-Related Secondary Lymphedema
Background
Cancer-related secondary lymphedema is a significant complication affecting patients, particularly those with breast cancer. The integration of RNA-sequencing and machine learning presents a novel approach to uncover potential biomarkers.
Data Highlights
The correction pertains to the GAPDH primer sequence in Table S1 of the supplementary data, which is crucial for accurate research applications.
Key Findings
The original article has been updated to reflect the corrected primer sequence.
Machine learning techniques are being explored for predictive modeling in lymphedema outcomes.
Integrated analyses of clinical data and RNA-sequencing may reveal new biomarkers.
Current guidelines emphasize the importance of risk assessment and management strategies for lymphedema.
Clinical Implications
Healthcare professionals should be aware of the updated primer sequence for accurate research applications.
Conclusion
The correction of the GAPDH primer sequence is crucial for the integrity of ongoing research in cancer-related secondary lymphedema.
